Real-World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: A Target Trial Emulation. (PubMed, Transplant Cell Ther) - Sep 27, 2026 - "Primary IPTW analyses showed no significant difference in OS and EFS between axi-cel and liso-cel. Secondary time-varying analyses suggested differences in OS hazards during longer follow-up, favoring axi-cel. Liso-cel demonstrated a more favorable safety profile, with lower risk of CRS and ICANS compared with axi-cel. These findings should be interpreted cautiously given differential follow-up between treatment groups and the potential for residual confounding."
Journal • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|
|
Amandeep Godara; Chia Jie Tan; Joshua Caballero; Lorenzo Villa Zapata; Mohammed Zuber; Payaningal R Somanath; Shaimaa Elshafie
|